Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.

In the multivariable analysis, lack of BTA exposure was associated with an increased risk of death and progression compared with denosumab, while zoledronic acid was associated with a higher risk of progression or death compared with denosumab, although the difference in OS did not reach statistical significance ( Figures 2C, D ).

also in 111,027 other papers